

Supplementary Table 5: IBD-related HCRU and costs in UC patients based on their first advanced therapy from 1L until censoring; pairwise comparison with IFX as reference after IPW adjustment

Health economic outcome parameters PPY	ADA (n=419) vs. IFX ¹	p-value ²	GOL (n=424) vs. IFX ¹	p-value ²	TOF (n=399) vs. IFX ¹	p-value ²	UST (n=443) vs. IFX ¹	p-value ²	VDZ (n=419) vs. IFX ¹	p-value ²
Number of IBD-related hospitalizations (events)	0.16 (0.37) vs. 0.28 (0.59)	<0.001	0.13 (0.82) vs. 0.28 (0.59)	<0.001	0.09 (0.30) vs. 0.29 (0.60)	0.004	0.10 (0.24) vs. 0.29 (0.60)	0.004	0.21 (0.53) vs. 0.28 (0.60)	0.13
Duration of IBD-related hospital stays (days)	1.9 (7.0) vs. 2.7 (7.1)	0.070	1.3 (8.2) vs. 2.8 (7.2)	0.006	1.2 (3.2) vs. 2.9 (7.4)	0.11	0.6 (1.5) vs. 2.9 (7.4)	<0.001	1.9 (6.6) vs. 2.8 (7.2)	0.094
Number of IBD-related surgeries (events)	0.16 (0.46) vs. 0.23 (0.64)	0.057	0.16 (0.29) vs. 0.23 (0.63)	0.10	0.08 (0.15) vs. 0.24 (0.65)	0.009	0.11 (0.40) vs. 0.24 (0.65)	0.078	0.22 (0.69) vs. 0.23 (0.64)	0.9
Duration of IBD-related sick-leave (days)	26 (51) vs. 26 (45)	>0.9	17 (33) vs. 26 (44)	0.059	8 (13) vs. 26 (44)	<0.001	11 (16) vs. 26 (44)	0.034	21 (49) vs. 26 (45)	0.3
Number of IBD-related sick-leave (events)	0.73 (1.02) vs. 1.10 (1.42)	<0.001	0.77 (0.89) vs. 1.09 (1.41)	0.018	0.55 (0.70) vs. 1.08 (1.40)	0.075	0.39 (0.46) vs. 1.08 (1.39)	<0.001	1.04 (1.50) vs. 1.08 (1.39)	0.8
Costs for IBD-specific hospitalizations (EUR)	1,161 (4,768) vs. 1,403 (3,444)	0.4	813 (4,041) vs. 1,398 (3,436)	0.035	624 (1,615) vs. 1,447 (3,510)	0.10	281 (637) vs. 1,446 (3,514)	<0.001	993 (2,631) vs. 1,417 (3,491)	0.11
Costs for IBD-specific medication (EUR)	14,521 (8,284) vs. 16,634 (10,362)	0.005	16,432 (9,941) vs. 16,611 (10,318)	0.9	17,930 (5,691) vs. 16,607 (10,317)	0.5	39,313 (15,504) vs. 16,578 (10,301)	<0.001	17,859 (9,320) vs. 16,585 (10,252)	0.15
Costs for IBD-specific outpatient treatment (EUR)	630 (325) vs. 777 (404)	<0.001	700 (445) vs. 775 (403)	0.2	705 (422) vs. 776 (406)	0.6	704 (499) vs. 775 (406)	0.6	844 (441) vs. 779 (406)	0.091
Total costs for IBD-specific treatment (EUR) ³	16,435 (9,374) vs. 18,929 (10,633)	0.001	18,102 (11,096) vs. 18,898 (10,589)	0.5	19,259 (5,627) vs. 18,946 (10,595)	0.9	40,299 (15,951) vs. 18,914 (10,580)	<0.001	19,784 (8,921) vs. 18,892 (10,550)	0.3
Total costs for all-cause treatment (EUR) ⁴	25,829 (14,415) vs. 27,355 (19,523)	0.2	27,829 (15,486) vs. 27,231 (19,543)	0.8	23,467 (6,439) vs. 27,383 (19,762)	0.093	108,232 (117,443) vs. 27,312 (19,700)	0.073	27,558 (16,855) vs. 27,239 (19,466)	0.8

ADA= Adalimumab IBD = Inflammatory bowel disease IFX = Infliximab IPW = inverse probability weighting HCRU = Healthcare resource utilization PPY = Per Patient Year UC = ulcerative colitis UST= Ustekinumab VDZ= Vedolizumab

¹Mean (SD), in ADA/GOL/TOF/VDZ/UST vs. IFX in UC patients

²Regression least-squares mean differences